India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment
12/02/2026 03:12
Feb 12 (Reuters) - India's Zydus Lifesciences ZYDU.NS said on Thursday that it and its U.S. unit have agreed to pay $120 million to Astellas Pharma 4503.T as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron. Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the U.S. from the date of the agreement until September 2027, the company said. (Reporting by Hritam Mukherjee in Bengaluru; Editing by Sherry Jacob-Phillips) ((mailto: hritam.mukherjee@thomsonreuters.com; @MukherjeeHritam;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn